Immunovia Publ Ab Stock Five Year Return
IMMNOV Stock | SEK 0.82 0.02 2.38% |
Immunovia publ AB fundamentals help investors to digest information that contributes to Immunovia Publ's financial success or failures. It also enables traders to predict the movement of Immunovia Stock. The fundamental analysis module provides a way to measure Immunovia Publ's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunovia Publ stock.
Immunovia |
Immunovia publ AB Company Five Year Return Analysis
Immunovia Publ's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
Competition |
According to the company disclosure, Immunovia publ AB has a Five Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Diagnostics & Research (which currently averages 0.0) industry. This indicator is about the same for all Sweden stocks average (which is currently at 0.0).
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
All Next | Launch Module |
Immunovia Fundamentals
Return On Equity | -0.38 | |||
Return On Asset | -0.26 | |||
Operating Margin | (201.30) % | |||
Current Valuation | 536.89 M | |||
Shares Outstanding | 22.63 M | |||
Shares Owned By Insiders | 36.15 % | |||
Shares Owned By Institutions | 4.60 % | |||
Price To Earning | (57.93) X | |||
Price To Book | 2.21 X | |||
Price To Sales | 683.47 X | |||
Revenue | 844 K | |||
Gross Profit | 15.81 M | |||
EBITDA | (135.47 M) | |||
Net Income | (166.63 M) | |||
Cash And Equivalents | 359.85 M | |||
Cash Per Share | 18.42 X | |||
Total Debt | 27.16 M | |||
Debt To Equity | 7.80 % | |||
Current Ratio | 14.26 X | |||
Book Value Per Share | 13.09 X | |||
Cash Flow From Operations | (152.65 M) | |||
Earnings Per Share | (7.80) X | |||
Target Price | 110.0 | |||
Number Of Employees | 64 | |||
Beta | 1.29 | |||
Market Capitalization | 479.62 M | |||
Total Asset | 493.81 M | |||
Z Score | 10.2 | |||
Net Asset | 493.81 M |
About Immunovia Publ Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovia publ AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovia Publ using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovia publ AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Immunovia Stock
Immunovia Publ financial ratios help investors to determine whether Immunovia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Immunovia with respect to the benefits of owning Immunovia Publ security.